BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 19932713)

  • 1. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases.
    Newton R; Leigh R; Giembycz MA
    Pharmacol Ther; 2010 Feb; 125(2):286-327. PubMed ID: 19932713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells.
    Kaur M; Chivers JE; Giembycz MA; Newton R
    Mol Pharmacol; 2008 Jan; 73(1):203-14. PubMed ID: 17901197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?
    Newton R; Holden NS
    Mol Pharmacol; 2007 Oct; 72(4):799-809. PubMed ID: 17622575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: rescue by long-acting beta2-adrenoceptor agonists.
    Rider CF; King EM; Holden NS; Giembycz MA; Newton R
    J Pharmacol Exp Ther; 2011 Sep; 338(3):860-9. PubMed ID: 21622733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
    Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
    Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and nongenomic effects of glucocorticoids.
    Stahn C; Buttgereit F
    Nat Clin Pract Rheumatol; 2008 Oct; 4(10):525-33. PubMed ID: 18762788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
    Schäcke H; Berger M; Rehwinkel H; Asadullah K
    Mol Cell Endocrinol; 2007 Sep; 275(1-2):109-17. PubMed ID: 17630119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA.
    Kiri VA; Bettoncelli G; Testi R; Viegi G
    Respir Med; 2005 Sep; 99(9):1115-24. PubMed ID: 15921904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-adrenoceptor responses of the airways: for better or worse?
    Broadley KJ
    Eur J Pharmacol; 2006 Mar; 533(1-3):15-27. PubMed ID: 16469310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticosteroids.
    Barnes PJ
    Handb Exp Pharmacol; 2017; 237():93-115. PubMed ID: 27796513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.
    Lindmark B
    Ther Adv Respir Dis; 2008 Oct; 2(5):279-99. PubMed ID: 19124378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic glucocorticoids versus non-steroidal glucocorticoid receptor modulators: survival of the fittest regulator of the immune system?
    De Bosscher K; Beck IM; Haegeman G
    Brain Behav Immun; 2010 Oct; 24(7):1035-42. PubMed ID: 20600811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glucocorticoids on gene transcription.
    Hayashi R; Wada H; Ito K; Adcock IM
    Eur J Pharmacol; 2004 Oct; 500(1-3):51-62. PubMed ID: 15464020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of action of glucocorticoids in asthma].
    Jaffuel D; Mathieu M; Godard P; Michel FB; Demoly P
    Rev Mal Respir; 1999 Sep; 16(4):431-42. PubMed ID: 10549054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory glucocorticoids: changing concepts.
    Newton R
    Eur J Pharmacol; 2014 Feb; 724():231-6. PubMed ID: 23747654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting inflammation using selective glucocorticoid receptor modulators.
    De Bosscher K; Haegeman G; Elewaut D
    Curr Opin Pharmacol; 2010 Aug; 10(4):497-504. PubMed ID: 20493772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
    BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
    Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma.
    van der Velden VH
    Mediators Inflamm; 1998; 7(4):229-37. PubMed ID: 9792333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
    Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
    COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.